These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18018406)

  • 21. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial.
    Grover SA; Lowensteyn I; Joseph L; Kaouache M; Marchand S; Coupal L; Boudreau G;
    Arch Intern Med; 2007 Nov; 167(21):2296-303. PubMed ID: 18039987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary: Geoffrey Rose's thinking about coronary artery disease.
    Faergeman O
    Int J Epidemiol; 2005 Apr; 34(2):246-7. PubMed ID: 15764696
    [No Abstract]   [Full Text] [Related]  

  • 23. A review of cardiovascular risk factors in US military personnel.
    McGraw LK; Turner BS; Stotts NA; Dracup KA
    J Cardiovasc Nurs; 2008; 23(4):338-44. PubMed ID: 18596497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study.
    de Rojas FD; De Frutos T; Ponte A; Chacón JM; Vitale GC;
    Prev Cardiol; 2009; 12(2):65-71. PubMed ID: 19476579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits of risk factor modification through cardiac rehabilitation.
    Borrás IC; Cruz-Jiménez M; Nadal E; Middelhoff A; Rivera A
    Bol Asoc Med P R; 2008; 100(4):75-9. PubMed ID: 19400532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screen detection and the WHO stepwise approach to the prevalence and risk factors of arterial hypertension in Kinshasa.
    Longo-Mbenza B; Ngoma DV; Nahimana D; Mayuku DM; Fuele SM; Ekwanzala F; Beya C
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):503-8. PubMed ID: 18830083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetes and hypertension in the Americas.
    Barceló A
    West Indian Med J; 2000 Dec; 49(4):262-5. PubMed ID: 11211530
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevalence of cardiovascular risk factors in grade nine students.
    Prentice D; Kilty HL; Stearne K; Dobbin SW
    Can J Cardiovasc Nurs; 2008; 18(3):12-6. PubMed ID: 18727282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive surveillance and treatment of dyslipidemia in the postinfarct patient: evaluation of a nurse-oriented management approach.
    Baillargeon JP; Lepage S; Larrivée L; Roy MA; Landry S; Maheux P
    Can J Cardiol; 2001 Jul; 17(7):767-8. PubMed ID: 11515497
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study.
    Hadaegh F; Harati H; Ghanbarian A; Azizi F
    East Mediterr Health J; 2009; 15(1):157-66. PubMed ID: 19469439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing cardiovascular disease in Kentucky: epidemiology, trends, and strategies for the future.
    Rugg SS; Bailey AL; Browning SR
    J Ky Med Assoc; 2008 Apr; 106(4):149-61; quiz 149, 162-3. PubMed ID: 18478845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?].
    Broedl UC; Lehrke M; Parhofer KG
    MMW Fortschr Med; 2008 Jun; 150(25):41-3. PubMed ID: 18705054
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S; Hilleman D
    Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing the patient with hypertriglyceridemia: a practical approach for nurse practitioners.
    Rankin FM; Cohen JD
    J Am Acad Nurse Pract; 2008 Dec; 20 Suppl 2():1-14; quiz 15. PubMed ID: 19143900
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prevention of arteriosclerotic heart and vascular diseases].
    Siedek H
    Wien Med Wochenschr; 1971 Jul; 121(30):575-81. PubMed ID: 5564652
    [No Abstract]   [Full Text] [Related]  

  • 38. Potential benefits of controlling coronary heart disease risk factors in the United Arab Emirates.
    Abdulle AM; Nagelkerke NJ; Abouchacra S; Obineche EN
    Kidney Blood Press Res; 2008; 31(3):185-8. PubMed ID: 18493155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma cholesterol levels continue to decline despite the rising prevalence of obesity: population trends in Perth, Western Australia, 1980-1999.
    Hobbs MS; Knuiman MW; Briffa T; Ngo H; Jamrozik K
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):319-24. PubMed ID: 18525387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Arterial hypertension and the kidney].
    Niang A
    Dakar Med; 2008; 53(1):1-6. PubMed ID: 19102111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.